Figure 7.

Recombinant tissue plasminogen activator targeted nanobubbles dissolve clots in the C3 gain-of function mouse model of atypical hemolytic uremic syndrome. (A) Representative image of glomerular fibrin deposition in saline-treated atypical hemolytic uremic syndrome (aHUS) mice (n=3), aHUS mice treated with rtPA-NB, (0,5 mg/g body weight; n=6) or aHUS mice treated with recombinant tissue plasminogen activator targeted nanobubbles (rtPA-tNB) (0,5 mg/g body weight; n=5). (B) Densitometry analysis of glomerular fibrin deposition, 87 glomeruli scored in saline-treated C3 gain of function (GOF), 358 glomeruli scored in rtPA-NB, 459 scored in rtPA-tNB. *P<0.05, **P<0.005, ***P<0.0001 using one-way ANOVA followed by Student-New-